News for Chimerix, Inc. (CMRX)

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

North Carolina-based Chimerix, Inc. (CMRX) is up over 69 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Transaction Overview On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 9,536,647 shares in Biof

**media[527622]**

**media[523712]**

One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.

Chimerix’s dordaviprone shows potential for glioma treatment with a possible FDA approval by 2025. Read why CMRX stock is a strong growth candidate.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.35%

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling by around 0.1% on Tuesday. The Dow traded down 0.02% to 44,393.25 while the NASDAQ...

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Tuesday. The Dow traded up 0.02% to 44,412.05 wh...

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down...

North Carolina-based Chimerix, Inc. (CMRX) is up over 163 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of C3.ai, Inc. AI rose sharply in today's pre-market trading session after the company reported better-than-expected second-quarter financial results. C...

UNICEF issues emergency tender for Monkeypox vaccines in collaboration with global health organizations.

Rapid Advancements of Innovative Antiviral “ COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

Investors are optimistic as we move into the third quarter earnings season.

The stock market crash of 2022 significantly depressed US equities’ valuations. In this backdrop, many believe now is the right time to buy stocks for long-term benefits.

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 115.3% to $1.40 in pre-market trading after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.